Skip to content

Sero-epidemiology of Priority Arboviruses in French Guiana

Sero-epidemiology of Priority Arboviruses in French Guiana

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03210363
Acronym
EPI-ARBO
Enrollment
2697
Registered
2017-07-06
Start date
2017-06-09
Completion date
2020-06-30
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arbovirus Infections

Brief summary

Dengue is an important public health problem despite the efforts of local health authorities to mitigate the impact of epidemics and the epidemiology of dengue evolved from an endemo-epidemic to a hyper-endemic state. In late 2013, the first local transmission of chikungunya virus in the Americas was identified in Caribbean countries and territories including French Guiana. Rapidly, more than 16,000 suspected local Health authorities had reported cases. In May 2015, the Pan American Health Organization (PAHO) issued an alert regarding the first confirmed Zika virus infections in Brazil. The emergence of Zika virus in South America led to a rapid spread throughout South and Central America, reaching French Guiana in December 2015. With the increasing frequency of epidemics related to arbovirus and the resulting health, social, and economic impacts of dengue, the surveillance of arbovirus have become social, political, and public health challenges that require specific and non-available immune status information.

Detailed description

French Guiana is a 250,000 inhabitant's French overseas department located in South America, the epidemiology of arboviruses has recently evolved and marked by important outbreaks. Dengue remains an important public health problem despite the efforts of local health authorities to mitigate the impact of epidemics and the epidemiology of dengue evolved from an endemo-epidemic to a hyper-endemic state. In late 2013, the first local transmission of chikungunya virus in the Americas was identified in Caribbean countries and territories including French Guiana. Rapidly, more than 16,000 suspected local Health authorities had reported cases. In May 2015, the Pan American Health Organization (PAHO) issued an alert regarding the first confirmed Zika virus infections in Brazil. The emergence of Zika virus in South America led to a rapid spread throughout South and Central America, reaching French Guiana in December 2015. With the increasing frequency of epidemics related to arbovirus and the resulting health, social, and economic impacts of dengue, the surveillance of arbovirus have become social, political, and public health challenges that require specific and non-available immune status information.

Interventions

Blood sample

Sponsors

Institut Pasteur
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
2 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Guiana resident for at least 6 months and present during the entire study period * Age between 2 and 75 years old

Exclusion criteria

* Subject under guardianship or deprived of liberty by judicial decision * Subject with any pathology or health problem not compatible with blood sampling

Design outcomes

Primary

MeasureTime frameDescription
Dengue, chikungunya, zika Antibodies detection by multiplex serologic tests2 yearsDescription of the virological status of individuals by Mutiplex detection of antibodies directed against dengue, chikungunya and zika arboviruses.

Secondary

MeasureTime frameDescription
Seroprevalence by area and age2 yearsEstimatation of the frequency of Dengue, Chikungunya and zika infections among the general population of French Guiana by geographical area and by age class

Other

MeasureTime frameDescription
Dengue infections proportion2 yearsProportion of dengue primary and multiple infections in Guiana population.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026